Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
Twitter Feed
-
A batch of 1000 liters of hydro-alcoholic solution produced by UCB is on its way to the EpiCURA hospital. Another batch is ready to be delivered to the governmental authorities. Read more https://t.co/ZUj0SeUUE9 https://t.co/InUceFrglw
— UCB News (@ucb_news) 03.04.2020 -
#Media: UCB completes the acquisition of Ra Pharmaceuticals – to deliver differentiated therapies to patients https://t.co/kjXt1qU0i8 https://t.co/2OLBqoYsGP
— UCB News (@ucb_news) 02.04.2020 -
UCB is working around the clock to protect the supply of medicines. Despite the challenges associated to the COVID-19 crisis, we have not experienced shortages of any of our products on the global market. https://t.co/pqXUlCCJgc
— UCB News (@ucb_news) 01.04.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
